unknown
Stage
1
Investors
About
Zag Bio develops thymus-targeted therapies using bifunctional antibodies to induce T cell central tolerance for the treatment of autoimmune diseases.
Explore Zag Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.